I know we expect to get P top line within the next handful
I know we expect to get P top line within the next handful of weeks, but other than that I am pretty sketchy as to the realistic timeline we can expect for further trial progress or news forthcoming from the company. Have no clue as to length of time needed for :
FDA to grant Expanded Access/Compassionate Use designation and exactly for what indications they will allow that for each drug and if successful how long to actually get the drugs to patients.
Time to prepare a P3 and actually bring it to recruitment
Time to formulate a topical cream for B dermatology indications and then time to get a P2 going (or would we need a quick P1 for a cream).
Time remaining to bring K and B to oral formulations
Time to get oral formulations accepted so that P2 trials could begin with them
Exactly how impactful as to time the Fast Track designation will be to get B to Oral Mucositis patients and Kevetrin to retinoblastoma patients.
The next 45 days should give us a pretty good idea as to the value of P, but until we then get a deal of significant monetary upfront value we could then go into another quiet period until further items mentioned above come to completion and justify further PRs.
I am in the camp that a deal of some magnitude will come forth soon after P top line results and that IPIX monetary position will greatly improve to prevent the need for further stock dilution to pay for operational expenses. But I do believe there will be some delay on further progress as to trials just due to the normal administrative requirements from the FDA as to getting anything done, regardless of Fast Track designation. The stock price will be dependent on the market and I hope it finally wises up to recognize the value of IPIX and knock the socks off those that have been holding it down, though I realize a lot of the holding down has been the need to issue stock regularly over the last 8 months or more to pay for trial costs.
Guess I am just preparing myself to the possibility that we could get great news regarding P very soon (expecting it with a high degree of confidence) but the expected deal(s) soon (though nobody knows exactly when) may be the only real booster for the share price so that we may not see a robust uptick in the share price right away as I and so many others were expecting.
It will then go back to accepting that the science is moving forward and we may have a bit longer to wait for the market to value us at what we all know should be at a vastly higher price.
1
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....
Continue Reading
Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....
Continue Reading
A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...
Continue Reading
A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...
Continue Reading
Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...
Continue Reading
Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...
Continue Reading
Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...
Continue Reading
A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...
Continue Reading
A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...
Continue Reading
August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...
Continue Reading
Top 5 Most Recently Viewed Articles
Alphabet's Q2 Earnings Report: A Focus on AI Growth Alphabet (NASDAQ: GOOGL), the parent company of Google, is poised to release its second quarter earnings soon. Many analysts and investors are keenly awaiting details that might reveal how the company’s artificial intelligence (AI) endeavors are transforming into tangible revenue streams. With the surge in interest...
Continue Reading
Important Notice for Dentsply Sirona Inc. Shareholders The Gross Law Firm has issued a notice for shareholders of Dentsply Sirona Inc. (NASDAQ: XRAY). Shareholders who acquired shares during the recently identified class period are encouraged to reach out regarding the opportunity to be appointed as lead plaintiff. Securing this position is not a prerequisite for...
Continue Reading
Insider Activity Spotlight on American Woodmark James Davis, a Board Member of American Woodmark (NASDAQ: AMWD), has made headlines recently by selling a significant number of shares, which has sparked various reactions in the market. Understanding Recent Transactions: In a recent SEC filing, it was reported that DAVIS sold 1,250 shares of American Woodmark, amounting to...
Continue Reading
Franchise ownership might just feel within reach for educators eying a new chapter, thanks to Ivybrook Academy’s fresh incentive. The renowned half-day preschool franchise is now offering a cool $5,000 cut off the initial franchise fee to educators diving into franchise ownership. It’s a nod to those who spend their days molding young minds. Opening Doors for...
Continue Reading
The Strategic Move to SAR Data Imagine this: You’re in the thick of a hurricane, where visibility goes out the window, and traditional satellite data chokes under the crushing weight of clouds and nightfall. That's the precise chaos ICEYE US is cutting through with its Synthetic Aperture Radar (SAR) technology. The latest scuttlebutt is that NOAA's getting cozy with...
Continue Reading